Only a couple of years since the first sickle cell disease (SCD) gene therapies gained U.S. FDA approval, researchers are working to expand access for younger children, and to improve manufacturing and commercialization to reach patients faster.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: J&D, Eli Lilly, Merakris, Uniqure.
Biopharma happenings, including deals and partnerships, and other news in brief: Alexion, Alzinova, Atossa, Astrazeneca, Formycon, Jyong, MS Pharma, Neurimmune, Orano, Propanc, Replicate, Roche, Sichuan Kelun, Vycellix.
Biopharma financing activity from January through November reveals an environment that has cycled through dramatic peaks and subsequent normalization. In November 2025, $9.94 billion was collected through 96 transactions, down in both value and volume from $13.23 billion from 137 transactions in October.
RSS
